Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Industry Rank Analysis: Shifting Into Overdrive
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Options Strategies & the Zacks Rank
- AWS 5/20: The Fed In Focus This Week
- PFP 5/20: Will We Touch 1700?
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/20/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ORBOTECH LTD | ORBK | 10.86% |
| SONIC FOUNDR | SOFO | 9.45% |
| VIPSHOP HOLD | VIPS | 9.20% |
| RENEWABLE EN | REGI | 8.98% |
| EAGLE BULK S | EGLE | 7.84% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Leading distributor of pharmaceuticals and medical supplies Cardinal Health ( CAH - Analyst Report ) recently announced it had been recognized as a Promising Practice by the Work Life Legacy Military Award. This award was bestowed by the Families and Work Institute (FWI) on account of the increased employment challenges as well as opportunities encountered by service personnel entering the civilian workforce.
The FWI is a renowned, non-partisan, non-profit think tank. This research body evaluates changes in the ranks of the employed and their families. It spots nascent trends and then carries out research that yields practical results. FWI created the Work Life Legacy Award to encapsulate the experience of those who led the Work Life movement in order to motivate others.
Cardinal Health was honored for its Transition and Mentoring program which is a training program that facilitates transition from service to civilian employment. With over two million military personnel slated to enter the civilian workforce by 2016, the need to help this cohort is a major domestic issue.
Cardinal Health is ranked among Fortune 500 companies. With over $100 billion in annual sales, Cardinal Health remains one of the largest distributors of pharmaceuticals and medical supplies in the U.S. The company’s diversified product portfolio may partly insulate it from the current economic uncertainty.
The company stands to gain from the gradual shift in mix from bulk to the higher-margin non-bulk sector of the Pharmaceutical segment. It is also riding the generic wave. Overall, Cardinal benefits from a spate of tuck-in acquisitions and capital deployment strategies.
However, the company faces tough competition across all business segments, which may continue to pressure pricing and margins. Its major competitors in the pharmaceutical supply chain segment include McKesson Corp. ( MCK - Analyst Report ) and AmerisourceBergen Corp. ( ABC - Analyst Report ) .
We have a long-term Neutral recommendation on Cardinal. The stock currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
Read the full Analyst Report on CAH
Read the full Analyst Report on ABC
Read the full Analyst Report on MCK